Barclays Maintains Overweight on Lumexa Imaging Hldgs, Raises Price Target to $17

Benzinga · 1d ago
Barclays analyst Andrew Mok maintains Lumexa Imaging Hldgs (NASDAQ:LMRI) with a Overweight and raises the price target from $13 to $17.